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Abstract
The cyclooxygenase (COX) pathway is currently targeted for therapeutic intervention in different cancers. We have
previously shown that silencing of COX-2 in the poorly differentiated metastatic breast cell line MDA-MB-231 by
RNA interference markedly delayed tumor onset and inhibited metastasis. To understand the functional effects of
COX-2 silencing underlying the inhibition of tumor growth and metastasis previously reported, we investigated
changes in these cells for a number of cancer-associated phenotypes. Cyclooxygenase-2–silenced cells were less
able to acidify tissue culture medium, a response that could partly be attributed to decreased lactate production or
export detected by reduced lactate in the medium. Consistent with the significantly reduced transcript levels of
hyaluronan synthase 2, an enzyme responsible for the total level of hyaluronan secreted by these cells, COX-2
silencing resulted in lower hyaluronan levels secreted in culture medium. Inhibition of human umbilical vein endo-
thelial cell network association in a coculture assay was also observed in COX-2–silenced cells. These data high-
light the functional role of COX-2 in pathways that mediate increased malignancy.
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Introduction
Cyclooxygenase 2 (COX-2) is a major contributor to invasive and
metastatic stimuli in prostate, colorectal, and breast tumors [1–6].
Cyclooxygenase 2 products are involved in processes central to tumor
growth, invasion, and metastasis including angiogenesis and response
to hypoxia [4–7]. We previously demonstrated that extrapulmonary
metastasis of MDA-MB-231 cells was dependent on COX-2 and
that COX-2–silenced MDA-MB-231 cells had increased levels of
antiangiogenic transcripts such as thrombospondin 1 and reduced
levels of prometastatic mRNA such as matrix metalloproteinase 1
[5]. In this study, we have examined the functional effects of
COX-2 silencing in MDA-MB-231 cells. We focused on lactate pro-
duction, extracellular acidosis, extracellular matrix (ECM) composi-
tion, and human umbilical vein endothelial cell (HUVEC) network
formation in COX-2–silenced cells because, as briefly outlined in the
subsequent paragraph, these mechanisms are associated with altered
metabolism, invasion, vascularization, and processes that result in
increased malignancy.
Increased glycolysis and an acidic extracellular pH are associated
with a more malignant phenotype. Increased glycolytic activity is me-
diated, in part, through the stabilization of hypoxia-inducible factor
(HIF), which in turn is thought to actively inhibit the conversion of
pyruvate to acetyl CoA [8]. Stabilization of the HIF proteins can also
up-regulate the expression of transmembrane proteins responsible
for the transport of the excess lactate produced outside the cell [9].
Increased lactate in the tumor microenvironment was found to in-
hibit the metabolism of cytotoxic T cells [10] suggesting that HIF-
facilitated accumulation of lactate in the tumor microenvironment
may confer advantages for tumor survival and growth. Extracellular
acidosis has been associated with increased secretion of proteolytic
enzymes and increased invasion and metastasis [11].
The ECM plays an important role in invasion, angiogenesis, and
metastasis [12]. We previously observed that COX-2 silencing af-
fects transcripts associated with the ECM [5] including hyaluronan
synthase 2 (HAS2). Hyaluronan maintains tissue integrity and mediates
adhesion, migration, and differentiation of cells during inflammation,
wound repair, and embryonic development [13,14]. It promotes tumor
Abbreviations: COX-2, cyclooxygenase 2; ECM, extracellular matrix; HAS2, hyaluronan
synthase 2; HIF, hypoxia-inducible factor; HUVEC, human umbilical vein endothelial
cells; PG, prostaglandin
Address all correspondence to: Zaver M. Bhujwalla, Department of Radiology, The
Johns Hopkins University School of Medicine, Rm 208C Traylor Bldg., 720, Rutland
Avenue, Baltimore, MD 21205. E-mail: zaver@mri.jhu.edu
1Grant information: This work was supported by the National Institutes of Health
research grants 2R01CA82337 and P50 CA103175.
Received 9 May 2008; Revised 22 July 2008; Accepted 29 July 2008
Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00
DOI 10.1593/neo.08568
www.neoplasia.com
Volume 10 Number 11 November 2008 pp. 1163–1169 1163
cell adhesion to laminin and may facilitate invasion through this mecha-
nism [15]. Inhibition of HAS2 using antisense RNA was also found to
reduce tumor formation by MDA-MB-231 cells in vivo [16].
Whereas the contribution of the hypoxic response to tumor neo-
vasculature formation has been extensively studied, other factors in-
cluding prostaglandins (the major products of the cyclooxygenase
reaction) have been shown to affect angiogenesis. Cyclooxygenase 2
overexpression in vivo increased microvascular density in the mam-
mary fat pad indicating that COX-2 plays a role in tumor angio-
genesis [4]. Human umbilical vein endothelial cell microtubule or
microfilament disruption was also found to elicit an increase in both
prostaglandins E2 and I2 (PGE2 and PGI2) secretion [17] suggesting
an association between COX-2 function and HUVEC network for-
mation. Additionally, PGE2 has previously been shown to increase
Akt phosphorylation and endothelial cell sprouting in a manner de-
pendent on the presence of endothelial nitric oxide synthase activity
[18]. Our investigation of the functional effects of COX-2 silencing
in MDA-MB-231 cells, specifically lactate production, extracellular
acidosis, hyaluronan production and secretion, and HUVEC net-
work formation, revealed significant differences between parental
and COX-2–silenced cells.
Materials and Methods
Cell Culture
All epithelial cells were cultured with RPMI 1640 medium (Sigma-
Aldrich, St. Louis, MO) supplemented with 8.25% fetal bovine serum
(Sigma-Aldrich) without penicillin or streptomycin. Supernatants were
collected at the times indicated. Cells used to isolate total RNA for the
microarray experiment were seeded (1 × 106) in 100-mm dishes
and allowed to attach to the plate overnight. Low-passage HUVEC
(Clonetics, Walkersville, MD) were cultured in endothelial growth
medium (EGM-2; Lonza, Switzerland) supplemented as described
by the manufacturer.
Microarray Analysis
RNA from COX-2–containing (MDA-MB-231) and COX-2–
silenced (Clone 2 and Pooled) cells was isolated as described
previously [5]. Samples were subjected to agarose formaldehyde
electrophoresis to determine the quality of the RNA by comparing
the ratios of 18S and 28S RNA species. All samples were run in com-
mercial arrays from Affymetrix (Santa Clara, CA), using Human Ge-
nome U133Plus 2.0 GeneChip arrays as described in the Affymetrix
Web site (http://www.affymetrix.com). Probe hybridization and
analysis was run as suggested by the manufacturer in the aforemen-
tioned Web site. These descriptions include all information currently
considered under the Minimum Information About a Microarray
Experiment supportive guidelines, with which the Johns Hopkins
Medical Institutions Microarray Core Facility abides in all its proce-
dures. Expression signals were obtained by Robust Multiarray Analy-
sis [19]. The posterior probabilities of the differential expression of
genes between the treatments were estimated with an empirical Bayes
method using Gamma-Gamma modeling by the bioconductor R pack-
age, EBarrays. The criterion of posterior probability >0.5 was used to
produce a list of genes significantly altered in COX-2–containing and
COX-2–silenced cells. Probeset IDs that were not similarly regulated
(within 1.5-fold) between Clone 2 and Pooled cells were discarded be-
cause the Clone 2 and Pooled clone cells have both been silenced for
COX-2 expression during the same transfection procedure as detailed
in Stasinopoulos et al. [5], and their common phenotype in vivo is likely
to be a result of similar changes in gene expression levels.
Lactate and Extracellular pH Measurements
For extracellular lactate measurements, cells (3 × 105) were plated
and media were collected at 24, 48, and 72 hours. Supernatant from
two independent experiments was assayed using a lactate assay kit
(BioVision, Mountain View, CA) following the instructions given
by the manufacturer.
For intracellular lactate measurements, cells were cultured to 80%
confluence and water-soluble and lipid extracts were obtained from
approximately 2 to 3 × 107 cells using the dual-phase extraction
method [20]. Cell extracts were resuspended in 0.6-ml deuterated
water (D2O) for magnetic resonance spectroscopy analysis. Five mi-
croliters of 0.75% (w/w) 3-(trimethylsilyl) propionic 2,2,3,3-d4 acid
sodium salt (TMSP) in D2O was used as an internal standard. Fully
relaxed 1H nuclear magnetic resonance spectra of the water-soluble
extracts were acquired on a Bruker Avance 500 spectrometer (Bruker
BioSpin Corp., Billerica, MA) as previously described [20]. Signal
integrals of two CH3 peaks in lactate at ∼1.3 ppm were determined
and normalized to cell numbers and compared to the standard. To
determine concentrations, peak integration (In) from
1H spectra for
lactate were compared to that of the internal standard TMSP accord-
ing to the equation:
lactate½  ¼ ATMSP • IlactateITMSP • Ncell
In this equation, [lactate] is the intracellular molar concentration per
cell of lactate expressed as mole per cell; I lactate and ITMSP represent
the signal integral of lactate and TMSP, respectively, divided by the
number of protons; ATMSP is the number of moles of TMSP in the
sample; and Ncell is the cell number.
For extracellular pH measurements, COX-2–containing (MDA-
MB-231 and Empty Vector) and COX-2–silenced (Clone 2 and
Pooled) cells were seeded (3 × 105) and allowed to attach overnight.
Fresh medium was added and supernatants collected from plates
at 24, 48, and 72 hours. Results represent four independent ex-
periments, and pH was measured at approximately 30°C using a
pH meter (MettlerToledo, Columbus, OH).
Real-time Reverse Transcription–Polymerase Chain Reaction
One-step real-time reverse transcription–polymerase chain reaction
(RT-PCR) was performed as previously described [5] using 10 ng of
total RNA isolated following the Qiagen RNeasy purification protocol
as described by the manufacturer (Qiagen, Valencia, CA). Primer
sequences for 18S transcript used as a control were 5′-GGTTGA-
TCCTGCCAGTAGC-3′ and 5′-GCGACCAAAGGA ACCATA-
AC-3′. QuantiTect real-time primers for HAS2 catalog numbers:
QT00027510 were purchased from Qiagen’s geneglobe collection.
Fold differences were calculated using the 2ΔΔC t method.
Hyaluronan Assay
Hyaluronan quantification from cell media was performed using
the Corgenix (Broomfield, CO) Hyaluronic Acid Quantitative Test
Kit essentially as described by the manufacturer with the parental
MDA-MB-231 media being diluted 1:100 in assay buffer and the
COX-2–silenced cells, Clone 2 and Pooled, diluted 1:10. Results
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shown represent values from three independent experiments. Stan-
dards were plotted using third-order polynomial regression as sug-
gested by the manufacturer, and a Student’s t test was performed
to determine statistical significance.
Immunoblot analysis
COX-2–containing and COX-2–silenced cells were seeded at 70%
confluence, allowed to attach overnight, then washed in PBS, and
lysed using M-PER lysis reagent (Pierce, Rockford, IL) plus protease
inhibitors (Sigma-Aldrich) at 1:500 dilution. Eighty micrograms of
protein was loaded on 10% gel and subjected to SDS-PAGE using
standard protocols, blocked for 1 hour for ROBO1 and CXCR4
and overnight for GAPDH in 5% nonfat dry milk in TBS–0.1%
Tween 20 and probed with ROBO1 (Invitrogen, Carlsbad, CA)
and CXCR4 (BD Biosciences) antibodies overnight and GAPDH
antibodies (Sigma-Aldrich) for 1 hour. Membranes were washed in
TBS–0.1% Tween 20 and secondary antibodies were added for
1 hour (GE Healthcare, Waukesha, WI) then washed with TBS–
0.1% Tween 20 and developed using SuperSignal West Pico (Pierce)
chemiluminescence substrate.
HUVEC–Epithelial Cell Coculturing Assay
Regular 24-well plates were coated with a paraffin pencil to reduce
surface tension, and 200 μl of 8.8 mg/ml ECM gel (Sigma-Aldrich)
was layered on the bottom of the plate and allowed to solidify in a
tissue culture incubator for 3 hours. Human umbilical vein endothelial
cell were trypsinized and stained with CellTracker Red (Invitrogen)
for 45 minutes in suspension as suggested by the manufacturer.
Human umbilical vein endothelial cell (1 × 105) were then mixed
with an equal number of unstained COX-2–containing (parental
MDA-MB-231, Empty Vector) and COX-2–silenced (Clone 2 and
Pooled) cells and plated on top of the ECM layer, and the cells were
returned to a tissue culture incubator. Photographs were taken using
a fluorescence-capable inverted microscope (Nikon, Melville, NY) at
different time points as indicated.
Results
Silencing of COX-2 Reduces Extracellular Acidification
Microarray analysis between COX-2–containing and COX-2–
silenced cells revealed significant reduction in the levels of transcripts
Figure 1. COX-2–silenced cells display reduced extracellular acidification and altered lactate metabolism and export. (A) Fold loss of
transcript levels associated with extracellular acidosis and lactate and glucose metabolism in COX-2–silenced Clone 2 and Pooled cells.
(B) Cell culture media lactate measurements from COX-2–containing parental MDA-MB-231 and Empty Vector cells and COX-2–silenced
Clone 2 and Pooled cells taken at the indicated time points. Results are normalized to MDA-MB-231 medium lactate at each time point.
Shown are mean ± SE from four experiments; *P < .05. (C) Intracellular lactate concentration in COX-2–containing parental MDA-MB-
231 and Empty Vector cells and COX-2–silenced Clone 2 and Pooled cells measured by 1H magnetic resonance spectroscopy as de-
scribed in the Materials and Methods section. Shown are mean + SE from five experiments. (D) pH measurements of cell culture media
from COX-2–containing parental MDA-MB-231 and Empty Vector cells and COX-2–silenced Clone 2 and Pooled cells at the indicated
time points. Shown are mean ± SE from four experiments; *P < .05; **P < .005.
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involved in the metabolic pathways including the glutamate trans-
porter SLC1A1, the lactate transporter SLC16A7 (or MCT-2),
the proton (H+) myo-inositol symporter SLC2A13, the glucose
transporter SLC2A1 (GLUT1), and hexokinase II (Figure 1A). To
determine the effect of COX-2 silencing on lactate export and
extracellular lactate, we collected media from cells at 24, 48, and
72 hours after seeding and assayed lactate in supernatants obtained
from these cells (Figure 1B). We observed a 20% to 30% reduc-
tion of lactate concentration in cell culture media, suggesting that
COX-2–silenced cells had decreased lactate production or export. To
measure intracellular lactate, we performed 1H magnetic resonance
spectroscopy on cell extracts collected from COX-2–silenced and
COX-2–containing cells. Cyclooxygenase 2 silencing resulted in a
small reduction of lactate production; however, that reduction was
not statistically significant (Figure 1C ). Cyclooxygenase 2–silenced
(Clone 2 and Pooled) and COX-2–containing (MDA-MB-231 and
Empty Vector) cells were seeded to 70% confluence, and the pH of
the supernatant was measured at 24, 48, and 72 hours after media
change. Our results show that COX-2–silenced cells acidified their
medium to a much lesser extent and at a slower rate than COX-2–
containing cells (Figure 1D). Consistent with these observations,
we routinely observed that confluent COX-2–silenced cells showed
more alkaline medium than parental cells as seen by the change
of color of the pH indicator phenol red present in regular RPMI
1640 media.
Silencing of COX-2 Reduces Extracellular Hyaluronan Levels
To examine whether COX-2 regulates HAS2 expression, we chal-
lenged cells with a natural stimulus of COX-2 production, IL-1β
(10 ng/ml). Results from real-time PCR suggested that COX-2–
silenced cells have less HAS2 mRNA than parental cells (Clone 2:
3.0-fold loss, Pooled: 1.9-fold loss) after IL-1β stimulation in two
independent experiments. Exogenous PGE2 regulated HAS2 mRNA
in COX-2–containing and COX-2–silenced cells to a similar extent
(data not shown). We then examined the presence of hyaluronan in
the medium of COX-2–containing and COX-2–silenced cells. We
found that COX-2–silenced cells had a significantly lower amount
of secreted hyaluronan in three independent experiments (Figure 2)
demonstrating that COX-2 regulates the expression of hyaluronan,
an important component of the ECM, in these cells.
Silencing of COX-2 Inhibits HUVEC Network Formation
Microarray analysis between COX-2–containing and COX-2–
silenced cells revealed significant reduction in the levels of transcripts
involved in angiogenesis and vascular integrity including CXCR4
[5], ROBO1, and MEF2C (Figure 3A). Immunoblot analysis for
CXCR4 and ROBO1 confirmed that the expression of these pro-
teins is reduced in COX-2–silenced cells (Figure 3B). We examined
the role of COX-2–containing and COX-2–silenced cells in HUVEC
network formation in a coculturing assay. Human umbilical vein en-
dothelial cell were mixed and cocultured on ECM gel with parental
MDA-MB-231, Empty Vector, Clone 2, and Pooled cells for 8 (Fig-
ure 3C) and 24 hours (Figure 3D) in at least three independent ex-
periments performed in multiple wells. Coculturing of HUVEC with
COX-2–containing cells resulted in HUVEC network formation
within 8 hours. However, the presence of COX-2–silenced cells caused
HUVEC clumping with little protrusion formation and minimal, if
any, HUVEC association, indicating that silencing of COX-2 actively
perturbed HUVEC network formation.
Discussion
We have previously shown that silencing COX-2 expression in
MDA-MB-231 cells reduced orthotopic tumor growth in SCID mice
and abolished extrapulmonary metastasis in an experimental model
of metastasis [5]. In the functional studies performed here, silencing
COX-2 expression in MDA-MB-231 cells resulted in a decrease of
lactate production or export, a decrease in medium acidification, a
decrease in the secretion of the ECM component hyaluronan, and
a reduction of HUVEC network formation.
We observed that extracellular lactate concentration and extracel-
lular acidification were reduced in COX-2–silenced cells. Microarray
results from COX-2–containing and COX-2–silenced cells revealed
alterations in transcripts regulating lactate (SLC16A7 or MCT2) and
glutamate transport (SLC1A1) as well as other glycolysis-related
transporters and enzymes involved in cancer progression such as hexo-
kinase II. Whereas MCT2 expression has been previously demonstrated
in neurons, high monocarboxylate levels found in the breast possibly
require active lactate transport [21]. It is possible that breast tumors
with a high inflammatory component use active lactate transporters
to increase glycolysis and further acidify the extracellular environment.
The decrease of lactate production or export and medium acidification
on COX-2 silencing is likely a result of the reduction of prostanoid
synthesis, because lactate transport can be mediated, in part, through
a PGE2-lactate exchange mechanism [22]. A second mechanism by
which silencing of COX-2 may have altered H+ export is through the
Na+/H+ exchanger given recent findings that LPS-induced in-
flammation was inhibited to a similar extent by a Na+/H+ exchange
pump inhibitor and the nonselective COX inhibitor indomethacin
in vivo [23].
Figure 2. Extracellular hyaluronan levels are reduced in COX-2–
silenced cells. Measurements of hyaluronan in cell culture media
from COX-2–containing parental MDA-MB-231 cells and COX-2–
silenced Clone 2 and Pooled cells at the indicated time points.
Shown are mean ± SE from three experiments. P values for Clone
2 and Pooled cells at 24 hours are .145 and .144, respectively; at
48 hours are .029 and .019, respectively; and at 72 hours are .0002
and .0004, respectively.
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Figure 3. COX-2–silenced cells inhibit HUVEC tubulogenesis. (A) Ratio of expression of angiogenesis-related transcripts in MDA-MB-231
cells over COX-2–silenced Clone 2 and Pooled cells. (B) Immunoblot analysis for ROBO1, CXCR4, and GAPDH in COX-2 containing
parental (231) and empty vector (EV) and COX-2–silenced Clone 2 and Pooled cells. (C) Fluorescent microscopy of live HUVEC cells
prestained with CellTracker Red and cocultured with COX-2–containing parental MDA-MB-231 or Empty Vector cells or COX-2–silenced
Clone 2 and Pooled cells on Matrigel for 8 hours. (D) Bright field photographs of live HUVEC and COX-2–containing parental MDA-MB-
231 or Empty Vector cells or COX-2–silenced Clone 2 and Pooled cells after coculturing on Matrigel for 24 hours. All images shown were
taken at 4× using a fluorescence-capable Nikon inverted microscope.
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We previously observed that silencing COX-2 in MDA-MB-231
cells modified the expression of several transcripts associated with
the ECM to a profile consistent with a less metastatic phenotype
explaining, in part, the inability of COX-2–silenced cells to metasta-
size in an experimental model of metastasis [5]. Previous microarray
analysis [5] as well as RT-PCR data showed that COX-2 reduced
mRNA expression of HAS2 in MDA-MB-231 cells resulting in
reduced hyaluronan production. Hyaluronan synthase 2–silenced
MDA-MB-231 cells were previously shown to have reduced primary
tumor formation [16] which may explain the reduced ability of COX-
2–silenced MDA-MB-231 cells to form primary tumors [5]. Prosta-
noids have previously been shown to regulate hyaluronan synthesis
through HAS2 in vascular smooth muscle cells a process linked to
atherogenesis [14]. Whereas several factors play a role in cell mi-
gration and angiogenesis [24,25], our data are consistent with these
earlier studies and suggest that silencing of COX-2 in poorly differen-
tiated MDA-MB-231 breast cancer cells may reduce the hyaluronan-
facilitated migration of the growing tumor and the proliferation and
migration of vascular smooth muscle endothelial cells required for
tumor angiogenesis.
The angiogenic phenotype is typically associated with aggressive
and metastatic tumors and COX-2–overexpressing tumors have in-
creased microvascular density [4]. Our finding that COX-2–silenced
MDA-MB-231 cells actively inhibited HUVEC network formation
when cocultured on an ECM gel adds to a growing body of evi-
dence suggesting that COX-2 plays an important role in angiogene-
sis [4,18,26], a process essential for primary and metastatic tumor
growth. Transcriptome comparisons between COX-2–containing
and COX-2–silenced cells revealed changes in several angiogenesis-
related transcripts such as CXCR4 and ROBO1. Western blot analyses
of CXCR4 and ROBO1 confirmed the reduction of these transcripts
at the protein level. CXCR4 is a chemokine receptor important in
cancer cell invasion [27] and angiogenesis [28], whereas ROBO1 is
a receptor of the leucine-rich repeat protein Slit2 that is important
for vascular guidance [29] and is overexpressed in breast cancer patient
samples as well as MDA-MB-231 cells [30]. It is thus possible that
loss of COX-2 expression and function reduces angiogenic signaling
mediated by CXCR4 and ROBO1 in poorly differentiated breast
tumors. Additionally, we reported loss in transcript levels of LEF1, a
transcription factor of the β-catenin pathway previously associated
with the induction of the proangiogenic factor IL-8 [31]. COX-2 si-
lencing resulted in the loss of platelet-derived growth factor D mRNA
levels previously shown to cooperate with vascular endothelial growth
factor E to promote angiogenesis [32]. COX-2 silencing resulted in the
loss of several proangiogenic factors explaining, in part, the inability
of HUVEC to form networks and self-associate and the marked re-
duction in orthotopic tumor growth previously reported [5]. We have
previously shown that COX-2–silenced MDA-MB-231 cells had sig-
nificantly elevated levels of thrombospondin 1 mRNA [5]. Increased
thrombospondin 1 expression may also contribute to the inhibition of
HUVEC network formation observed by Yamauchi et al. [33].
In conclusion, COX-2 silencing resulted in the loss of several func-
tional phenotypic characteristics associated with malignancy in poorly
differentiated MDA-MB-231 breast cancer cells including extracellular
acidification, hyaluronan production, and HUVEC network forma-
tion. Cyclooxygenase 2 silencing resulted in the loss of expression of
metabolic symporters, HAS2, and several proangiogenic factors. Our
data implicate COX-2 as a regulator of processes central to tumor
metabolism, angiogenesis, and ECM composition, making it a major
contributor to a microenvironment permissive to tumorigenesis, inva-
sion, and metastasis.
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